QPPV.COM KNOWLEDGE ASSESSMENT

Nirsevimab Classification, Mechanism, Safety and Pharmacovigilance Assessment

Test your understanding of the concepts covered by Nirsevimab: Classification, History, Mechanism of Action, Safety and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Why should first-season infants and children receiving second-season prophylaxis generally be analysed separately?

They always receive identical doses and therefore cannot be compared. Second-season recipients are selected because of greater vulnerability, creating important differences in baseline risk. Only second-season recipients can experience hypersensitivity. First-season recipients are not exposed to RSV.

Question 2 of 10 Which follow-up dataset would be most useful for evaluating suspected immune thrombocytopenia after nirsevimab?

Only the caregiver's assessment of whether the child looked pale. Baseline and nadir platelet counts, timing, bleeding phenotype, infections, recent medicines or vaccines, work-up and recovery. Only the RSV season and product presentation. Only the presence or absence of injection-site redness.

Question 3 of 10 In a first-season infant, why must body weight be retained in the pharmacovigilance record?

Weight determines whether the event can be reported to regulators. Weight is relevant to selecting the intended dose and identifying possible underdosing or presentation-selection errors. Weight determines whether RSV can infect the child. Weight is needed only for assessing injection-site pain.

Question 4 of 10 Which combination would provide the strongest evidence for evaluating a suspected nirsevimab breakthrough case?

Caregiver recollection of a cough without dose or test information. Exact dose and administration date, weight, symptom onset, laboratory method, severity and clinical risk factors. Only the child's age and whether symptoms occurred during winter. Only the product lot number and injection-site appearance.

Question 5 of 10 A negative rapid RSV antigen test is obtained from an infant with a clinical picture strongly suggestive of RSV. What approach is most consistent with the article?

Conclude that nirsevimab prevented infection despite the clinical findings. Assume all RSV assays are invalid after antibody prophylaxis. Consider confirmatory RT-PCR because the diagnostic method is part of the effectiveness evidence chain. Label the result as laboratory-confirmed RSV.

Question 6 of 10 A child develops laboratory-confirmed RSV eight months after receiving nirsevimab. Which is the most appropriate initial interpretation?

The case automatically demonstrates antibody resistance. The case should be interpreted in light of time since administration and possible waning exposure before concluding that it represents biological failure. The case proves that the product interferes with RSV diagnostic assays. The case cannot be assessed because all RSV occurring after prophylaxis is expected.

Question 7 of 10 What is the principal pharmacological purpose of the YTE Fc substitutions in nirsevimab?

To increase viral mutation rates and accelerate immune recognition. To enhance recycling through the neonatal Fc receptor and extend systemic persistence. To convert the antibody into an active vaccine antigen. To enable the antibody to replicate inside respiratory epithelial cells.

Question 8 of 10 Which factor would most strongly support a focused virological investigation of reduced nirsevimab susceptibility?

One mild cough with no RSV test. Recurring sequence patterns across severe, laboratory-confirmed breakthrough cases. A common fever after simultaneous routine vaccination. A local injection-site reaction without systemic symptoms.

Question 9 of 10 Why is absence of reported RSV disease in a treated individual insufficient to establish product effectiveness?

Nirsevimab has no preventive activity in individuals without symptoms. Individual observation lacks information about exposure and requires an appropriate population denominator and comparator. All treated children are expected to develop RSV. Only adverse-event reports can be used to assess effectiveness.

Question 10 of 10 Which statement best reflects the regulatory status of immune thrombocytopenia described in the article?

It is an established causal adverse reaction with a confirmed incidence. It is a potential serious-risk signal under regulatory evaluation, not proof of causality. It is a contraindication for every child receiving nirsevimab. It has been definitively ruled out as unrelated to nirsevimab.

Nirsevimab Classification, Mechanism, Safety and Pharmacovigilance Assessment

Cookie Settings